Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Signal Transducer and Activator of Transcription 3 (STAT3) is frequently activated in various cancers, driving tumor initiation, progression, and drug resistance.
• Targeting persistently activated STAT3 represents a promising strategy for developing novel anticancer therapies.

Purpose of the Study:

• To identify and characterize a novel small-molecule inhibitor of STAT3 for potential cancer therapy.
• To evaluate the efficacy of the identified inhibitor, ODZ10117, in preclinical cancer models.

Main Methods:

• Discovery of ODZ10117, a small molecule targeting the SH2 domain of STAT3.
• Assessment of ODZ10117's inhibitory effects on STAT3 phosphorylation, dimerization, nuclear translocation, and transcriptional activity.
• Evaluation of ODZ10117's anti-cancer effects in vitro and in vivo breast cancer models, including migration, invasion, apoptosis, tumor growth, and metastasis.

Main Results:

• ODZ10117 selectively targets the STAT3 SH2 domain, inhibiting its activity more potently than existing STAT3 inhibitors.
• ODZ10117 demonstrated significant suppression of breast cancer cell migration and invasion.
• In vivo studies showed that ODZ10117 reduced tumor growth and lung metastasis, extending survival rates.

Conclusions:

• ODZ10117 is a novel and potent small-molecule inhibitor of STAT3.
• ODZ10117 exhibits significant anticancer activity in preclinical models and holds promise for the development of new STAT3-targeted cancer therapeutics.